聚乙二醇修饰脂质体阿霉素联合顺铂单次给药治疗晚期骨肉瘤的剂量递增试验
Pegylated Liposomal Doxorubicin Combined with Cisplatin for Advanced Osteosarcoma: A Single-dose Dose-escalating Trial
- 中山大学学报（医学科学版） 2020年41卷第4期 页码：582-588
- 作者机构：
1.中山大学肿瘤防治中心生物治疗中心//黑色素瘤与肉瘤内科， 广东 广州 510060
2.北京积水潭医院骨肿瘤科，北京 100000
- 作者简介：
文习之，博士，主治医师，研究方向：黑色素瘤及肉瘤的临床与基础研究，E-mail：wenxzh@sysucc.org.cn
潘求忠，共同第一作者
- 基金信息：国家自然科学基金(81772863)
DOI：
中图分类号： R738收稿：2020-01-07，
纸质出版：2020-07-15
- 稿件说明：
移动端阅览
文习之,潘求忠,翁德胜等.聚乙二醇修饰脂质体阿霉素联合顺铂单次给药治疗晚期骨肉瘤的剂量递增试验[J].中山大学学报（医学科学版）,2020,41(04):582-588.
WEN Xi-zhi,PAN Qiu-zhong,WENG De-sheng,et al.Pegylated Liposomal Doxorubicin Combined with Cisplatin for Advanced Osteosarcoma: A Single-dose Dose-escalating Trial[J].Journal of Sun Yat-sen University(Medical Sciences),2020,41(04):582-588.
文习之,潘求忠,翁德胜等.聚乙二醇修饰脂质体阿霉素联合顺铂单次给药治疗晚期骨肉瘤的剂量递增试验[J].中山大学学报（医学科学版）,2020,41(04):582-588. DOI：
WEN Xi-zhi,PAN Qiu-zhong,WENG De-sheng,et al.Pegylated Liposomal Doxorubicin Combined with Cisplatin for Advanced Osteosarcoma: A Single-dose Dose-escalating Trial[J].Journal of Sun Yat-sen University(Medical Sciences),2020,41(04):582-588. DOI：
摘要
目的
2
为了探索聚乙二醇修饰脂质体阿霉素(PLD)联合顺铂在骨肉瘤化疗中PLD的最大耐受剂量(MTD)。
方法
2
纳入经病理确诊的转移性或不可切除的骨肉瘤患者14例，接受1个周期的PLD联合顺铂方案化疗。PLD分为3个剂量水平(40、50和60 mg/m
2
，第1天)，每个剂量组计划入组3例患者，按3+3方法进行剂量递增；顺铂(100 mg/m
2
，分成4 d使用)的剂量保持不变；每21 d一个疗程。受试者在化疗结束后48 h接受粒细胞刺激因子预防性升白细胞治疗。按照NCI CTCAE v4.0统计不良反应。
结果
2
纳入研究的患者中有男性9例，女性5例，中位年龄为20 (14～43)岁。在PLD剂量递增至60 mg/m
2
剂量组，入组的2例患者均出现3级口腔黏膜炎合并4级中性粒细胞减少性发热，达到剂量限制性毒性，因此下调一个剂量等级。在50 mg/m
2
剂量组，一共入组9例患者，仅1例患者出现剂量限制性毒性，表现为4级血小板减少持续大于3 d。在入组的所有患者中，观察到的3～4级不良反应为中性粒细胞下降(12例，12/14)、血小板减少（7例，7/14）、贫血（4例，4/14）及口腔黏膜炎(2例，2/14)。所有不良反应经对症、支持治疗后均可缓解，无治疗相关死亡。
结论
2
在PLD联合顺铂治疗晚期骨肉瘤的化疗方案中，PLD的最大耐受剂量为50 mg/m
2
，主要剂量限制性毒性为口腔黏膜炎及中性粒细胞减少性发热，不良反应经对症治疗后可缓解。
Abstract
Objective
2
To explore the maximum tolerated dose (MTD) of pegylated liposome doxorubicin (PLD) when combined with cisplatin as a modified regimen for osteosarcoma.
Methods
2
A total of 14 patients with pathologically confirmed metastatic or unresectable osteosarcoma received one cycle of PLD combined with cisplatin therapy. The study used a traditional 3+3 design
with three PLD dose levels (40
50
and 60 mg/ m
2
day 1). It was designed to recruit three patients initially at each dose level. Cisplatin was given at a dose of 100 mg/m
2
(administered within four days) for each patients. Patients received prophylactic granulocyte stimulating factor therapy 48 h after chemotherapy. Toxicities were documented according to the the National Cancer Institute Common Terminology Criteria for Adverse Events
version 4.0 (NCI CTCAE v4.0).
Results
2
Of the 14 patients
9 were male and 5 female
with a median age of 20 years (range 14~43). Both of the patients at dose level of 60 mg/m
2
experienced dose-limiting toxicity (DLT) (grade 3 oral mucositis and grade 4 neutropenic fever). Only 1 of the 9 patients at dose level of 50 mg/m
2
experienced DLT (grade 4 thrombocytopenia lasting for more than 3 days) and thus the MTD was 50 mg/m
2
. Most common grade 3~4 adverse events across all cohorts included neutropenia (12 cases
12/14)
thrombocytopenia (7 cases
7/14)
anemia (4 cases
4/14) and oral mucositis (2 cases
2/14). All the adverse events were relieved after symptomatic and supportive treatment. No treatment-related death was observed.
Conclusions
2
For advanced osteosarcoma
when combined with cisplatin
the MTD of PLD was 50 mg/m
2
. The main DLT was oral mucositis and neutropenic fever. The adverse events can be relieved after symptomatic treatment.
关键词
Keywords
references
Federman N , Bernthal N , Eilber FC , et al . The multidisciplinary management of osteosarcoma [J]. Curr Treat Options Oncol , 2009 , 10 ( 1-2 ): 82 - 93 .
Marina NM , Smeland S , Bielack SS , et al . Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial [J]. Lancet Oncol , 2016 , 17 ( 10 ): 1396 - 1408 .
Yu D , Zhang S , Feng A , et al . Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation [J]. Medicine (Baltimore) , 2019 , 98 ( 19 ): e15582 .
Gabizon A , Shmeeda H , Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies [J]. Clin Pharmacokinet , 2003 , 42 ( 5 ): 419 - 436 .
Kaminskas LM , McLeod VM , Kelly BD , et al . A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems [J]. Nanomedicine , 2012 , 8 ( 1 ): 103 - 111 .
Blank N , Laskov I , Kessous R , et al . Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin [J]. Cancer Chemother Pharmacol , 2017 , 80 ( 4 ): 737 - 743 .
Schmitt CJ , Dietrich S , Ho AD , et al . Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin′s lymphoma patients with cardiac risk factors [J]. Ann Hematol , 2012 , 91 ( 3 ): 391 - 397 .
O′Brien ME , Wigler N , Inbar M , et al . Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer [J]. Ann Oncol , 2004 , 15 ( 3 ): 440 - 449 .
Biermann JS , Chow W , Reed DR , et al . NCCN guidelines insights: bone cancer, version 2.2017 [J]. J Natl Compr Canc Netw , 2017 , 15 ( 2 ): 155 - 167 .
Negrão MV , da Silva Rocha LS , da Motta Girardi D , et al . Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma [J]. Anticancer Drugs , 2017 , 28 ( 8 ): 915 - 921 .
Judson I , Radford JA , Harris M , et al . Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group [J]. Eur J Cancer , 2001 , 37 ( 7 ): 870 - 877 .
李远 , 黄真 , 单华超 , 等 . 骨肉瘤脂质体多柔比星与多柔比星新辅助化疗单中心非随机对照研究 [J]. 中华肿瘤防治杂志 , 2019 , 26 ( 15 ): 1124 - 1128
Li Y , Huang Z , Shan HC , et al . Single-center,non-randomized controlled study of doxorubicin and doxorubicin in neoadjuvant chemotherapy for osteosarcoma [J]. Chin J Cancer Prev Treat , 2019 , 26 ( 15 ): 1124 - 1128 .
沈维娜 , 季冬梅 , 薛恺 , 等 . 聚乙二醇脂质体阿霉素在CHOP方案治疗侵袭性非霍奇金淋巴瘤中的Ⅰ期剂量递增试验的安全性探索 [J]. 中华血液学杂志 , 2016 , 37 ( 12 ): 1044 - 1048
Shen WN ， Ji DM ， Xue K , et al . A phase l dose-escalating trial of pegylated liposomai doxorubicin in combination with cyclophosphamide, vincristine and prednisone for aggressive non—Hodgkin lymphoma [J]. Chin J Hematol , 2016 , 37 ( 12 ): 1044 - 1048 .
Cheng M , Song Z , Qi Y , et al . A dose-escalating pilot study (NCT03017404) of pegylated liposomal doxorubicin and cyclophosphamide, followed by docetaxel administration as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer [J]. Oncol Res Treat , 2019 , 42 ( 5 ): 269 - 274 .
吴启权 , 吴剑秋 , 汤唯艳 , 等 . 多柔比星脂质体对DLBCL化疗致手足综合征的危险因素分析及防治措施 [J]. 药学与临床研究 , 2017 , 25 ( 3 ): 217 - 220 .
Wu QQ , Wu JQ , Tang WY , et al . Risk factors of pegylated liposomal doxorubicin induced hand-foot syndrome in diffuse large B cell lymphoma patients and the prophylactico-therapeutic measures [J]. Pharmaceutical and Clinical Research , 2017 , 25 ( 3 ): 217 - 220 .
0
浏览量
1016
下载量
1
CSCD
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：广州市中山二路74号 中山大学北校园办公楼前座一楼 邮编：510080
- 联系电话：020-87690764，87690974，87690694 Email：xbmed@mail.sysu.edu.cn
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
